Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 23 Feb 2023

Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)

in Cancer Molecular Targets and Therapeutics

Xiao-Dong Jiao
Bao-Dong Qin
Zhan Wang
Ke Liu
Ying Wu
Yan Ling
Wen-Xing Qin
Miao-Miao Wang
Ling-Yan Yuan
Savio George Barreto

Frontiers in Oncology

doi 10.3389/fonc.2023.860711

4,061 views
5 citations

Original Research

Published on 22 Feb 2023

The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study

in Cancer Molecular Targets and Therapeutics

Zhiyong Liu
Xin Wang
Jiaqiang Wang
Peng Zhang
Chao Li
Bangmin Wang
Songtao Gao
Oufei Liu
Weitao Yao

Frontiers in Oncology

doi 10.3389/fonc.2023.1124517

2,002 views
5 citations

Case Report

Published on 22 Feb 2023

Case Report: The effective treatment of patients in advanced no-small cell lung cancer patients with EGFR G719X/S768I/L861Q and acquired MET amplification: A case series and literature review

in Cancer Molecular Targets and Therapeutics

Yun Zhao
Cuiyun Su
Lina Shi
Wenqi Luo
Zhen Liu
Chuqiao Liang
Huilin Wang
Ruiling Ning
Qitao Yu
Wei Jiang

Frontiers in Oncology

doi 10.3389/fonc.2023.1126325

2,830 views
2 citations

Mini Review

Published on 20 Feb 2023

ARID1A in cancer: Friend or foe?

in Cancer Molecular Targets and Therapeutics

Beatrice Fontana
Giulia Gallerani
Irene Salamon
Ilaria Pace
Roberta Roncarati
Manuela Ferracin

Frontiers in Oncology

doi 10.3389/fonc.2023.1136248

13,450 views
24 citations

Original Research

Published on 16 Feb 2023

Molecular features and predictive models identify the most lethal subtype and a therapeutic target for osteosarcoma

in Cancer Molecular Targets and Therapeutics

Kun Zheng
Yushan Hou
Yiming Zhang
Fei Wang
Aihua Sun
Dong Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1111570

3,518 views
2 citations

Review

Published on 16 Feb 2023

Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer

in Cancer Molecular Targets and Therapeutics

Yinghao Zhao
Shengnan Jia
Kun Zhang
Lian Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1064616

3,993 views
6 citations

Case Report

Published on 13 Feb 2023

Positive response to niraparib in chemo-refractory patients with metastatic appendiceal mucinous adenocarcinoma harboring ATM mutations: A case report

in Cancer Molecular Targets and Therapeutics

Junhui Wang
Huijuan He
Wansu Xu
Jianxin Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1010871

1,714 views
2 citations

Original Research

Published on 10 Feb 2023

High GNG4 predicts adverse prognosis for osteosarcoma: Bioinformatics prediction and experimental verification

in Cancer Molecular Targets and Therapeutics

Xiaohong Jiang
Fuxing Tang
Junlei Zhang
Mingwei He
Tianyu Xie
Haijun Tang
Jianhong Liu
Kai Luo
Shenglin Lu
Yun Liu

Frontiers in Oncology

doi 10.3389/fonc.2023.991483

3,539 views
1 citation

Original Research

Published on 09 Feb 2023

GPX3 expression was down-regulated but positively correlated with poor outcome in human cancers

in Cancer Molecular Targets and Therapeutics

Qingyi Hu
Jiaoshun Chen
Wen Yang
Ming Xu
Jun Zhou
Jie Tan
Tao Huang

Frontiers in Oncology

doi 10.3389/fonc.2023.990551

6,194 views
13 citations

Clinical Trial

Published on 09 Feb 2023

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

in Cancer Molecular Targets and Therapeutics

Paolo A. Ascierto
Eleonora Cioli
Vanna Chiarion-Sileni
Pietro Quaglino
Francesco Spagnolo
Massimo Guidoboni
Michele Del Vecchio
Ketty Peris
Paola Queirolo
Luisa Fioretto

Frontiers in Oncology

doi 10.3389/fonc.2023.1107307

3,148 views
1 citation

Case Report

Published on 09 Feb 2023

Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas

in Cancer Molecular Targets and Therapeutics

Elise F. Nassif
Cissimol P. Joseph
Rossana Lazcano
Jocelyn T. Joseph
Prapassorn Thirasastr
Alexander J. Lazar
Neeta Somaiah

Frontiers in Oncology

doi 10.3389/fonc.2023.1046442

1,847 views
1 citation

Original Research

Published on 08 Feb 2023

CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma

in Cancer Molecular Targets and Therapeutics

Shen Xue
Xiao-min Su
Li-na Ke
Yu-gang Huang

Frontiers in Oncology

doi 10.3389/fonc.2023.1077780

3,973 views
9 citations

Original Research

Published on 08 Feb 2023

Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models

in Cancer Molecular Targets and Therapeutics

Daniel J. Sisler
Trista K. Hinz
Anh T. Le
Emily K. Kleczko
Raphael A. Nemenoff
Lynn E. Heasley

Frontiers in Oncology

doi 10.3389/fonc.2023.1094123

6,644 views
7 citations

Original Research

Published on 06 Feb 2023

A novel Cuprotosis-related signature predicts the prognosis and selects personal treatments for melanoma based on bioinformatics analysis

in Cancer Molecular Targets and Therapeutics

Bingqian Hu
Alphonse Houssou Hounye
Zheng Wang
Min Qi
Jianglin Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1108128

3,154 views
2 citations

Review

Published on 02 Feb 2023

Relationship between NUDT21 mediated alternative polyadenylation process and tumor

in Cancer Molecular Targets and Therapeutics

Shan Xiao
Huan Gu
Li Deng
Xiongtao Yang
Dan Qiao
Xudong Zhang
Tian Zhang
Tao Yu

Frontiers in Oncology

doi 10.3389/fonc.2023.1052012

4,015 views
5 citations

Original Research

Published on 02 Feb 2023

Effects of plasma-derived exosomes from the normal and thin Bactrian camels on hepatocellular carcinoma and their differences at transcriptome and proteomics levels

in Cancer Molecular Targets and Therapeutics

Hongqiang Yao
Siriguleng Yu
Yuchen Luo
Ming Wang
Xiuying Wang
Siriguleng Xu
Yufei Chen
Zhifeng Xie

Frontiers in Oncology

doi 10.3389/fonc.2023.994340

2,232 views
1 citation